BRPI0407384A - piridinas-triazóis como compostos antiinflamatórios - Google Patents

piridinas-triazóis como compostos antiinflamatórios

Info

Publication number
BRPI0407384A
BRPI0407384A BRPI0407384-3A BRPI0407384A BRPI0407384A BR PI0407384 A BRPI0407384 A BR PI0407384A BR PI0407384 A BRPI0407384 A BR PI0407384A BR PI0407384 A BRPI0407384 A BR PI0407384A
Authority
BR
Brazil
Prior art keywords
sup
sub
alkyl
hydrogen
group
Prior art date
Application number
BRPI0407384-3A
Other languages
English (en)
Inventor
John Frederick Braganza
Michael Anthony Letavic
Kim Francis Mcclure
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0407384A publication Critical patent/BRPI0407384A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

"PIRIDINAS-TRIAZóIS COMO COMPOSTOS ANTIINFLAMATóRIOS". A presente invenção relaciona-se a novas piridinas-triazóis de fórmula (I) em que X é >CH~ 2~, >NH, enxofre, >S=O, >SO~ 2~ ou oxigênio; em que p dito >CH~ 2~ e >NH podem opcionalmente ser substituídos com um substituinte adequado; R¬ 1¬ é selecionado do grupo consistindo de hidrogênio, alquil (C~ 1~-C~ 6~) e outros substituintes adequados; R¬ 2¬ é selecionado do grupo consistindo de hidrogênio, alquil (C~ 1~-C~ 6~;) e outros 10 substituintes adequados; s é um número inteiro de 0-4; R¬ 3¬ é R¬ 4¬, R¬ 5¬-(NR¬ 6¬)- , R¬ 5¬- S-, R¬ 5¬(S-O)-, R¬ 5¬(SO~ 2~)-, R¬ 5¬-SO~ 2~-NR¬ 6¬ -, R¬ 5¬(NR¬ 6¬)-SO~ 2~-, R¬ 5¬-O-, R¬ 5¬- (C=O) -, R¬ 5¬- (NR¬ 6¬) - (C=O) -, R¬ 5¬- (C=O) -NR¬ 6¬, R¬ 5¬- O- (C=O) -, R¬ 5¬- (C=O) -O-, R¬ 5¬-CR¬ 7¬=CR¬ 8¬ ou R¬ 5¬-C=C-; tal que o peso molecular de R¬ 3¬ é menor que 500 AMU, preferivelmente menor que 250 AMU; R¬ 4¬, R¬ 5¬ e R¬ 6¬ são cada selecionados de um grupo consistindo de hidrogênio, alquil (C~ 1~-C~ 6~) e outros substituíntes adequados; ou um sal farmaceuticamente aceitável deles; intermediários para sua preparação, para composições farmacêuticas os contendo e para seus usos medicinais. Os compostos da presente invenção são inibidores potentes de MAP quinases. Eles são úteis no tratamento de inflamação, osteoartrite, artrite reumatóide, câncer, reperfusão ou ataque isquêmico isquemia ou ataque cardíaco, doenças autoimunes e outras desordens.
BRPI0407384-3A 2003-02-14 2004-02-03 piridinas-triazóis como compostos antiinflamatórios BRPI0407384A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44778703P 2003-02-14 2003-02-14
PCT/IB2004/000363 WO2004072072A1 (en) 2003-02-14 2004-02-03 Triazolo-pyridines as anti-inflammatory compounds

Publications (1)

Publication Number Publication Date
BRPI0407384A true BRPI0407384A (pt) 2006-02-21

Family

ID=32869645

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407384-3A BRPI0407384A (pt) 2003-02-14 2004-02-03 piridinas-triazóis como compostos antiinflamatórios

Country Status (10)

Country Link
US (1) US7321040B2 (pt)
EP (1) EP1601672B1 (pt)
JP (1) JP2006517580A (pt)
AT (1) ATE334131T1 (pt)
BR (1) BRPI0407384A (pt)
CA (1) CA2515190A1 (pt)
DE (1) DE602004001676T2 (pt)
ES (1) ES2264795T3 (pt)
MX (1) MXPA05008568A (pt)
WO (1) WO2004072072A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012119B1 (ru) 2004-08-12 2009-08-28 Пфайзер Инк. ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ
US20090209577A1 (en) * 2004-08-18 2009-08-20 Pfizer Inc. Novel Triazolopyridine Compounds
BRPI0514391A (pt) * 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos de triazolopiridina para o tratamento de inflamação
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2007063868A1 (ja) * 2005-11-29 2007-06-07 Toray Industries, Inc. アリールメチレンウレア誘導体及びその用途
US20090012079A1 (en) * 2006-02-09 2009-01-08 Russell Andrew Lewthwaite Triazolopyridine Compounds
WO2008001929A1 (en) 2006-06-28 2008-01-03 Aska Pharmaceutical Co., Ltd. Treatment agent for inflammatory bowel disease
BRPI0716239A2 (pt) * 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
AU2008215659B2 (en) 2007-02-16 2012-11-01 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
JP2010523725A (ja) 2007-04-16 2010-07-15 レオ ファーマ アクティーゼルスカブ 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CA2691448A1 (en) * 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
US8119658B2 (en) * 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008328882A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as PI3K inhibitors
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
CA2752693A1 (en) 2009-02-17 2010-08-26 Chiesi Farmaceutici S.P.A. Triazolopyridine derivatives as p38 map kinase inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
MY167216A (en) 2011-12-09 2018-08-14 Chiesi Farm Spa Kinase inhibitors
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
UA115320C2 (uk) 2011-12-09 2017-10-25 К'Єзі Фармачеутічі С.П.А. Інгібітори кінази
EP2875014B1 (en) 2012-07-17 2017-11-29 Washington University Anti-mucus drugs and uses therefor
RU2015151886A (ru) 2013-06-06 2017-06-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибиторы киназ
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
KR20260008165A (ko) 2019-02-12 2026-01-15 스미토모 파마 아메리카, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
WO2024052685A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3050525A (en) * 1960-12-14 1962-08-21 John B Bicking Certain derivatives of s-triazolo [4, 3-a]-pyridine
BE640616A (pt) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
EP0727998B1 (en) * 1993-11-08 2004-01-21 Smithkline Beecham Corporation Oxazoles for treating cytokine mediated diseases
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en) * 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
WO2000040243A1 (en) * 1999-01-08 2000-07-13 Smithkline Beecham Corporation Novel compounds
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
DE50112961D1 (de) * 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
HUP0303415A2 (hu) * 2001-03-09 2004-01-28 Pfizer Products Inc. Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
AP2002002460A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel benzimidazole anti-inflammatory compounds.
DE60205974T2 (de) 2001-04-04 2006-06-29 Pfizer Products Inc., Groton Neue Benzotriazole mit entzündungshemmender Wirkung
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US7012143B2 (en) * 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
WO2004020609A2 (en) 2002-08-30 2004-03-11 Tufts University Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
WO2004020438A2 (en) * 2002-08-30 2004-03-11 Pfizer Products Inc. Novel processes and intermediates for preparing triazolo-pyridines
US7037923B2 (en) * 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) * 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas

Also Published As

Publication number Publication date
ES2264795T3 (es) 2007-01-16
US7321040B2 (en) 2008-01-22
EP1601672A1 (en) 2005-12-07
DE602004001676D1 (de) 2006-09-07
US20050075365A1 (en) 2005-04-07
WO2004072072A1 (en) 2004-08-26
ATE334131T1 (de) 2006-08-15
CA2515190A1 (en) 2004-08-26
EP1601672B1 (en) 2006-07-26
MXPA05008568A (es) 2005-11-04
JP2006517580A (ja) 2006-07-27
DE602004001676T2 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
BRPI0407384A (pt) piridinas-triazóis como compostos antiinflamatórios
KR102670486B1 (ko) 마크로사이클릭 면역조절제
EA200300864A1 (ru) Триазолопиридины в качестве противовоспалительных средств
ES2598503T3 (es) Nuevos citostáticos nucleósidos 7-deazapurina
ES2199250T3 (es) Derivados de monofosfatos de nucleosidos, un procedimiento para su produccion y su uso como farmacos supresores de inmunidad.
TWI758300B (zh) 免疫調節劑化合物
AU695032B2 (en) Purine and guanine compounds as inhibitors of PNP
DOP2002000349A (es) Nuevos compuestos antiinflamatorios de bencimidazol
FI104176B (fi) Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi
Hafez et al. Synthesis of substituted thieno [2, 3-d] pyrimidine-2, 4-dithiones and their S-glycoside analogues as potential antiviral and antibacterial agents
CA2379903A1 (en) Novel benzotriazoles anti-inflammatory compounds
PT821690E (pt) Análogos de nucleotídeos para tratamento de infeções virais
KR20030032944A (ko) 피리도[2,3-ｄ]피리미딘 및 피리미도[4,5-ｄ]피리미딘뉴클레오시드
UY27535A1 (es) Benzamida , heteroarilamida y amidas inversas,
JP2022539830A (ja) Ｐｄ－ｌ１阻害剤としてのインダン
SE0302116D0 (sv) Novel compounds
AR046077A1 (es) Derivados de n4- oxicarbonilcitimidina, procedimientos de eleaboracion y usos de los mismos
WO2004020438A3 (en) Novel processes and intermediates for preparing triazolo-pyridines
ES2699452T3 (es) Nuevo derivado de triazina
EP1885722A4 (en) CHINOLINE DERIVATIVES AS EP4 ANTAGONISTS
RU2011153706A (ru) Многосекционные композиции на основе амфифильных функциональных молекул или макромолекул
JP2010519179A (ja) ヌクレオシドおよび四級炭素中心を有するヌクレオチド類似体ならびに使用方法
JP2007503420A (ja) グリコーゲンホスホリラーゼ阻害活性を保有する複素環式アミド誘導体
EA200970002A1 (ru) Двойственные молекулы, содержащие пероксидное производное, их синтез и их терапевтические применения
CN104693256A (zh) 吉西他滨衍生物、含该衍生物的组合物及所述衍生物的制药用途

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.